Viridian Therapeutics reported that its elegrobart REVEAL‑1 Phase III trial met its primary endpoint, achieving a proptosis responder rate of 54 % with the once‑every‑four‑weeks (Q4W) dosing schedule and 63 % with the once‑every‑eight‑weeks (Q8W) schedule, compared with 18 % for placebo at week 24. The study also showed complete diplopia resolution in 51 % of patients on the Q4W arm versus 16 % on placebo, and the drug was generally well tolerated with low rates of hearing impairment and tinnitus.
The results confirm that a subcutaneous delivery platform can produce clinically meaningful benefit in active thyroid eye disease, the first evidence of such an approach in this indication. However, the placebo‑adjusted proptosis responder rates of 36 % (Q4W) and 45 % (Q8W) fell short of the 51‑73 % range that many investors had anticipated, raising concerns about elegrobart’s commercial viability relative to the intravenous standard of care, teprotumumab (Tepezza). Viridian’s CEO, Steve Mahoney, said, "We are excited to report these results from REVEAL‑1, the largest pivotal clinical trial conducted in active TED to date, which position elegrobart as potentially the first ever subcutaneous autoinjector treatment for TED."
Management emphasized the trial’s statistical significance and the convenience of the dosing schedule. Mahoney added, "REVEAL‑1 met its primary endpoint with high statistical significance. Elegrobart treatment drove robust proptosis responses in a treatment regimen comprised of as few as three subcutaneous doses. Further, in the Q4W arm, we saw clinically meaningful diplopia responses and diplopia resolution." Dr. Prem Subramanian, a professor of ophthalmology, noted, "Subcutaneous elegrobart showed rapid and clinically meaningful reductions in proptosis and diplopia in REVEAL‑1 with a highly convenient, well‑tolerated dosing profile. Patients are seeking more treatment choices for TED, and there remains a clear need for a more conveniently administered therapy."
The market reaction was muted, with investors focusing on the lower-than‑expected efficacy numbers. Shares of Viridian fell sharply after the announcement, reflecting concerns that the drug’s efficacy may not be sufficient to capture a sizable share of the $4 billion‑plus TED market, which is projected to grow to more than $4 billion by 2032. Analysts noted that while the trial met its primary endpoint, the modest placebo‑adjusted responder rates could limit the drug’s competitive positioning against teprotumumab and other pipeline candidates. Some analysts maintained buy ratings, citing the convenience advantage and the company’s strong cash position of $875 million at the end of 2025, which should support continued development and potential FDA submission in 2027.
Viridian plans to advance elegrobart in the REVEAL‑2 trial and to pursue regulatory approval in 2027. The company’s leadership remains confident that the subcutaneous platform can ultimately deliver a differentiated product, but the company will need to demonstrate superior efficacy or a clear value proposition to overcome the current headwinds. The REVEAL‑1 milestone provides a critical data point for the company’s strategy, but the path to commercial success will hinge on future trial outcomes and the ability to address investor concerns about efficacy relative to existing therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.